Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
81
resultados
Última actualización
02/08/2026 [07:28:00]
Resultados 25 a 50 de 81
Resumen de: CN122075518A
The invention belongs to the technical field of transplanted vascular remodeling diagnosis and treatment, and discloses application of a reagent for inhibiting or detecting Fasn and a medicine for preventing and/or treating transplanted vascular remodeling. Experimental research discovers that a group of novel macrophages capable of self-synthesizing lipid exist in the transplantation blood vessel reconstruction process, and Fasn is remarkably activated, so that intracellular lipid accumulation is caused, and the macrophages are promoted to be converted into foam cells. In-vitro studies show that by inhibiting the activity of the Fasn enzyme or down-regulating the expression of the Fasn enzyme, the transformation of macrophages to foam cells can be obviously inhibited, and the synthesis of lipid in cells can be reduced. Based on the discovery, the nucleic acid medicine constructed by adopting the siRNA is used for treating and/or relieving transplanted vascular remodeling. In-vivo experiments further prove that the nucleic acid medicine can remarkably inhibit intimal hyperplasia of transplanted blood vessels and reduce the neointimal/medial membrane ratio, so that the therapeutic effect is achieved. The method has a good application prospect.
Resumen de: CN122081482A
The invention provides a poor collateral circulation biomarker UBE2L3 and application thereof, and belongs to the technical field of biomedicine. According to the application disclosed by the invention, the key effect of the UBE2L3 in inhibiting the formation of the chronic coronary artery complete occlusion collateral circulation is defined for the first time, and the 'UBE2L3-Parkin-Drpl' axis is determined as a key endogenous inhibition pathway for regulating and controlling the CTO collateral circulation. The invention provides a clear intervention target with a clear mechanism for developing a brand new precise therapy for promoting therapeutic angiogenesis, solves the problems of unstable curative effect and off-target risk caused by a wide target in a current angiogenesis promoting strategy, provides a brand new non-surgical biological treatment strategy aiming at enhancing endogenous angiogenesis ability, and has a wide application prospect. Myocardial ischemia is expected to be improved essentially, so that the risk of adverse events such as long-term myocardial infarction and heart failure is reduced.
Resumen de: CN122081474A
The invention belongs to the technical field of biological medicines, and discloses a new mutation c.311Ggt of a TNNT2 gene related to dilated cardiomyopathy. A. Family genetic analysis and in-vitro function verification prove that the mutation causes enhanced sensitivity of myocardial cells to doxorubicin and fragmentation of a mitochondrial network, and the mutation has pathogenicity. On the basis, the invention provides a specific detection primer pair and a kit, which are used for rapid gene diagnosis and risk assessment of dilated cardiomyopathy.
Resumen de: CN122071740A
The invention belongs to the technical field of biological medicine and molecular biology, and particularly relates to application of carbonic anhydrase IV in prevention and treatment of coronary microangiopathy. The research proves that the carbonic anhydrase IV has the effects of maintaining the activity of human microvascular endothelial cells, promoting the development of heart microvessels and protecting the barrier function of the microvessels. It is shown that the carbonic anhydrase IV can play a role in inhibiting CMVD lesion by preventing heart microvascular density reduction and inhibiting heart microvascular permeability increase in the CMVD process, and therefore the carbonic anhydrase IV has good potential practical application value.
Resumen de: US20260139229A1
0000 Provided herein are multilineage cardiovascular organoids and methods of generating the same. In some aspects, provided herein is a system comprising a plurality of multilineage cardiovascular organoids derived from embryoid bodies. The embryoid bodies can be aggregated from pluripotent stem cells of varying genotypes. The multilineage cardiovascular organoids and systems described herein may be used for screening of agents, such as anti-cancer agents, for cardiotoxicity.
Resumen de: CN122060852A
The invention discloses a biomarker and a kit for diagnosing post-stroke depression qi deficiency and blood stasis, liver depression and qi stagnation. The biomarker comprises Clcn3 and/or Nco7. According to the application, by constructing animal models with various diseases and combining ELISA and qPCR technologies, multi-dimensional verification is carried out on candidate targets, and expression changes of the candidate targets in the models are confirmed. Further, by drawing an ROC curve, the diagnostic efficiency (including AUC value, sensitivity and specificity) of each candidate marker is evaluated. Besides, an AAV-mediated RNA interference function experiment is comprehensively applied, a biomarker with diagnosis potential is deeply excavated, and a molecular basis is provided for objective diagnosis of syndromes.
Resumen de: CN122060858A
The invention provides a kit for diagnosing acute myocardial infarction, and belongs to the field of functions and application of genes. The kit comprises a primer pair used for detecting the expression quantity of the NEO-1 gene, a forward primer is SEQ ID NO.1, and a reverse primer is SEQ ID NO.2. By means of the primer pair, the expression quantity of the NEO-1 gene in peripheral blood can be detected, and compared with non-coronary heart disease patients, the expression of NEO-1 in peripheral blood of AMI patients is increased. The expression increase of NEO-1 is found to be an independent risk factor of AMI, and the expression quantity of NEO-1 in peripheral blood of an AMI patient can be used as one of biomarkers of AMI.
Resumen de: CN122060855A
The invention discloses an application of circWHSC1 as a biomarker in preparation of a product for diagnosing or treating ineffective recanalization after ischemic stroke. According to the present invention, the circRNA sequencing results show that the expression of the circWHSC1 (including hsacirc0001388 and nucirc0001336) in the ineffective recanalization patient body is significantly reduced, and the circWHSC1 is verified in the mouse brain tissue, the plasma and the thrombus model of the tMCAO model; functional studies show that the circWHSC1 can significantly reduce the cerebral infarction volume of the mouse. The circWHSC1 can be used for early diagnosis, risk assessment, severity judgment, curative effect monitoring and prognosis judgment of invalid recanalization, and can be used as a drug target for screening candidate drugs for preventing or treating invalid recanalization. The invention provides a molecular diagnosis marker and a therapeutic target for invalid recanalization, and has important clinical value.
Resumen de: CN122055460A
Disclosed herein are methods, compositions, and devices for diagnosing and treating diseases, including cardiovascular diseases as well as such diseases and dysfunctions associated with administration of cancer therapy. Methods include sequencing a set of regions in a cell-free nucleic acid molecule and detecting one or more biomarkers indicative of cardiovascular disease and dysfunction.
Resumen de: CN122031507A
The invention relates to medical application of IRF9 in prevention and treatment of trastuzumab (TRZ) cardiotoxicity, and belongs to the technical field of biological medicine. The invention reveals that the expression of the interferon regulatory factor 9 (IRF9) in the TRZ cardiotoxic myocardial tissue is up-regulated for the first time, and myocardial damage is aggravated by promoting pyroptosis of myocardial cells. On the basis, the invention provides the IRF9 as a diagnostic marker of TRZ cardiotoxicity, and provides an application of an IRF9 low expression vector or small interfering RNA (siRNA) in preparation of drugs for preventing or treating TRZ cardiotoxicity. Animal experiments show that cardiac function decline, cardiac hypertrophy and fibrosis caused by TRZ can be remarkably improved by myocardial cell specific low-expression IRF9. The invention provides a new target spot and an intervention strategy for clinical prevention and treatment of TRZ cardiotoxicity.
Resumen de: CN122031686A
The invention relates to a method for producing an animal model of heart failure. The method comprises the step of weakening or deleting DDB1 protein function in myocardial cells of the animal model. The present application demonstrates that nuclear DDB1 co-agglomerates with MEF2C to control NAD + biosynthesis as well as ion homeostasis genes in the heart, and the lack of which results in the development of HFpEF. Development of HFpEF in a'double strike 'mouse model can be reversed through AAV-mediated DDB1 overexpression in myocardial cell nucleuses. Therefore, it is detected that DDB1 coordinates NAD + biosynthesis and ion homeostasis to protect the heart from being affected by ejection fraction retention heart failure caused by obesity, and the scheme of the application has therapeutic significance on treatment of obesity/diabetes HFpEF.
Resumen de: CN122038557A
The invention belongs to the technical field of molecular biology diagnosis and treatment, and relates to application of a reagent for detecting or inhibiting FN1 and a product for diagnosing or preventing and treating vascular restenosis. The expression level of the FN1 in a vascular restenosis sample is remarkably increased, and the FN1 can promote phenotypic transformation of vascular smooth muscle cells (VSMC). Meanwhile, further research proves that the FN1 has better diagnosis efficiency on the diagnosis of the vascular restenosis, and is higher in sensitivity, specificity and accuracy, so that the FN1 can be used for effectively diagnosing the vascular restenosis. In addition, in-vivo experiments prove that VSMC phenotypic transformation can be inhibited and vascular restenosis can be improved by inhibiting FN1 expression. The invention provides a new direction for research and development of vascular restenosis related diagnosis and prevention and treatment products, and has a good clinical application prospect.
Resumen de: CN122005802A
The invention provides application of an NCOA3 polyQ structural domain in preparation of a medicine for relieving ocular vascular abnormal hyperplasia diseases, relates to the technical field of biomedicine, and aims to solve the problems that in the prior art, an ocular pathological angiogenesis mechanism is complex, and safe and effective targeted intervention means are lacked. The construction of a mouse corneal micropocket pathological angiogenesis model proves that Nco3polyQ structural domain deletion can significantly inhibit corneal neovascularization: compared with a WT mouse, the Nco3wt/Q mouse corneal tissue CD31 positive signal is reduced, the number of corneal neovascularization in the Nco3Q/Q mouse is minimum, and the CD31 positive area is minimum; meanwhile, qPCR (quantitative polymerase chain reaction) detection of corneal tissues shows that mRNA (messenger ribonucleic acid) expression of the vascular marker genes Pecam1 and Cdh5 is in a decreasing trend and is further decreased in an Nco3Q/Q mouse. On the basis, the intervention strategy aiming at the NCOA3 polyQ structural domain is used for preparing the medicine for relieving the abnormal hyperplasia diseases of the ocular blood vessels, and a new treatment strategy and a potential target are provided for related diseases of the ophthalmology department.
Resumen de: CN122012694A
The invention discloses application of ACSS2 as an action target in screening or preparing a medicine for preventing or treating virus-induced vascular remodeling diseases, and belongs to the field of biological medicine. It is found that by inhibiting ACSS2 gene expression or protein activity, Zika virus induced vascular smooth muscle cell phenotypic transformation can be remarkably reversed, and occurrence and development of angiotensin II/aminopropionitrile induced aortic aneurysm/dissection are relieved. The invention provides a siRNA sequence (SEQ ID NO.1-2) specifically targeting ACSS2 and a pharmaceutical composition containing the siRNA, and provides a novel treatment target and a precise intervention tool for virus-related vascular remodeling diseases.
Resumen de: CN122012735A
The invention discloses a human MTHFR (methylenetetrahydrofolate reductase), MTRR (methylenetetrahydrofolate reductase) and SLC19A1 gene detection kit. The kit is based on a high-resolution melting curve analysis technology, and comprises four groups of primer pairs aiming at C677T and A1298C sites of MTHFR genes, A66G sites of MTRR genes and A80G sites of SLC19A1 genes. The kit can be used for rapidly, sensitively and accurately identifying the genotypes of the four key sites under the same reaction procedure by detecting the melting temperature of PCR products and the difference of curve shapes. The kit is suitable for risk assessment of cardiovascular diseases and birth defects, is more innovatively applied to donor screening and receptor assessment of coprophilous fungus transplantation, fills the blank of genetic background detection tools in the field, and has the advantages of low cost, high sensitivity, high specificity, simplicity and convenience in operation, high repeatability, quick and objective detection result and the like.
Resumen de: CN122012515A
The invention belongs to the technical field of biological medicine and molecular biology, and provides a hypertrophic cardiomyopathy virulence gene MYH7c.794Cgt; the invention relates to T (p.Thr265Ile) and an application thereof. The MYH7 gene mutation is located on the ninth exon, the 794th base is mutated from C to T, namely ACC is mutated to ATC, and the 265th amino acid in the coded amino acid sequence is mutated from threonine to isoleucine. The mutation induces cardiac hypertrophy by disrupting energy metabolism-this defect occurs prior to the occurrence of systolic dysfunction. Along with increasingly prominent status of precision medicine in cardiovascular treatment, a treatment strategy aiming at an upstream pathological process (such as energy homeostasis and mitochondrial dysfunction) provides a way with a wide prospect for preventing and treating MYH7-related hypertrophic cardiomyopathy. MYH7 gene screening has important values in the aspects of promoting early diagnosis, guiding timely treatment intervention and realizing risk-based prevention and management.
Resumen de: CN121987795A
The invention discloses an application of an IP6K1 gene, an IP6K1 protein and a PAS-A protein fragment in screening and preparing a medicine for preventing and/or treating myocardial infarction diseases or a medicine for improving myocardial cell injury caused by hypoxia. Through research, it is found for the first time that IP6K1 protein is directly combined with a PAS-A substructure domain of HIF-1alpha, and then degradation of the HIF-1alpha, formation of HIF-1alpha/ARNT dimer and combination of the HIF-1alpha and p53 are affected, so that repair of myocardial cell damage caused by hypoxia by the HIF-1alpha is limited, and cell death is aggravated; therefore, the influence caused by myocardial infarction is aggravated. When the IP6K1 gene is knocked out, or the expression of the IP6K1 gene is inhibited, or the IP6K1 protein is degraded, or the expression of a subdomain PAS-A protein fragment of the HIF-1alpha is increased, the combination of the IP6K1 protein and the HIF-1alpha can be eliminated, so that the positive effect of the HIF-1alpha is improved, the repair of myocardial cell injury is improved, the cell survival is promoted, and the adverse influence caused by myocardial infarction is reduced.
Resumen de: CN121992094A
The invention relates to a molecular marker for diagnosis, prognosis evaluation and treatment of cardiac fibrosis, and belongs to the technical field of biological medicines. The invention provides a molecular marker capable of diagnosing cardiac fibrosis, evaluating the severity of cardiac fibrosis, evaluating the prognosis of cardiovascular diseases accompanied with cardiac fibrosis or evaluating the prognosis of acute myocardial infarction. The molecular marker comprises a hepatocyte growth factor. Research finds that the HGF is remarkably increased in plasma of a patient with cardiac fibrosis, and the plasma HGF level of a patient with aortic valve stenosis is also remarkably increased before an operation, so that the HGF can be used for diagnosing cardiac fibrosis and evaluating the severity of cardiac fibrosis. Researches find that timely transient increase of the HGF in plasma of a patient with acute myocardial infarction is significantly related to good prognosis, and continuous low-level increase, continuous high-level increase, recurrence and delayed increase of the HGF are significantly related to poor prognosis, so that the HGF can be used for evaluating prognosis of acute myocardial infarction.
Resumen de: US20260128175A1
The present disclosure provides systems and methods for machine learning classification and assessment of disease based on gene expression data. In an aspect, a method for determining a disease state of a subject may comprise: (a) assaying a biological sample obtained or derived from the subject to produce a data set comprising gene expression measurements of the biological sample at each of a plurality of disease-associated genomic loci; (b) computer processing the data set to determine the disease state of the subject; and (c) electronically outputting a report indicative of the disease state of the subject. In some embodiments, the plurality of disease-associated genomic loci comprises single nucleotide polymorphisms (SNPs). In some embodiments, the disease comprises a lupus condition. In some embodiments, the disease comprises cardiovascular disease (CVD).
Resumen de: CN121975930A
The invention relates to application of tsRNA-3025a as a prognostic marker of acute myocardial infarction and a treatment target spot of myocardial ischemia reperfusion injury. A DNA (Deoxyribonucleic Acid) sequence corresponding to the tsRNA-3025a is shown as SEQ ID NO: 1: 5 '-ATCCTGCCGACTACGCCA-3'. The tsRNA-3025a can be used for treating acute myocardial infarction and myocardial ischemia reperfusion injury. In the aspect of prognosis, a detection kit is provided, and the risk of heart failure and short-term adverse events of a patient is evaluated by quantitatively detecting the expression level of the tsRNA. In the aspect of treatment, the invention provides the application of the anti-tagomir for inhibiting the function or expression of tsRNA-3025a in the preparation of the medicine for treating the myocardial ischemia reperfusion injury, and the anti-tagomir is subjected to specific chemical modification. A novel biomarker is provided for prognosis risk stratification of acute myocardial infarction, and an effective treatment strategy is provided for prevention and treatment of myocardial ischemia-reperfusion injury.
Resumen de: CN121978344A
The invention relates to application of a myocardial injury marker RSPO1 in preparation of a product for identifying cardiovascular diseases. The invention evaluates the expression profiles of all LGR4 ligands under cardiovascular diseases at present, provides the application of RSPO1 as a potential drug target, and further provides the application of the myocardial injury marker RSPO1 in preparation of products for identifying cardiovascular diseases based on the application. The invention also provides application of the reagent for detecting the RSPO1 protein level in preparation of products for diagnosing cardiovascular diseases. According to the invention, the problem of insufficient adaptability and specificity of the existing marker is solved, RSPO1 is developed into a diagnostic marker, a DY4645-05 ELISA kit is adopted for detection and adaptation of multiple samples such as serum, multiple cardiovascular diseases can be diagnosed, cross-species application is realized, a basic research and clinical diagnosis detection system is unified, and powerful support is provided for diagnosis and treatment of cardiovascular diseases.
Resumen de: CN121975935A
The invention provides a primer composition for detecting hereditary thrombophilia related gene mutation and application of the primer composition, and relates to the technical field of gene detection. The primer composition comprises a PCR (Polymerase Chain Reaction) amplification primer and an extension primer, wherein the PCR amplification primer is used for carrying out specific amplification on 24 single nucleotide polymorphic sites of 22 genes, and the extension primer is used for carrying out single base extension on the 24 single nucleotide polymorphic sites. According to the primer composition, by selecting twenty-four specific loci of twenty-two genes covering key systems such as coagulation, anticoagulation and the like, a detection system which is adaptive to genetic characteristics of specific people and takes pathopoiesis and risk factors into account is constructed, so that the limitation of race heterogeneity of conventional indexes is effectively overcome; and major mutation and a multi-gene minor accumulation effect can be captured at the same time, so that individual genetic susceptibility is comprehensively analyzed, and a systematic and accurate basis is provided for accurate screening and diagnosis and treatment of hereditary thrombophilia.
Resumen de: CN121975726A
The invention relates to a method for separating myocardial cell-derived small extracellular vesicles from in-vitro plasma in vitro and application of the myocardial cell-derived small extracellular vesicles. The method comprises the following steps: (1) providing a ligand capable of being specifically combined with a raney base receptor 2 protein RYR2; (2) separating total small cell extracellular vesicles from the in-vitro plasma sample; (3) co-incubating the ligand and total small extracellular vesicles, so that the ligand is specifically combined with the small extracellular vesicles which are derived from myocardial cells and express RYR2 on the surface, and a ligand-vesicle compound is formed; (4) combining the ligand-vesicle compound with a solid-phase carrier so as to separate the myocardial cell-derived extracellular vesicles of which the surfaces express RYR2 from the mixture; and (5) washing and/or eluting the ligand-vesicle compound combined on the solid-phase carrier to obtain enriched small extracellular vesicles derived from myocardial cells.
Resumen de: CN121975932A
The invention relates to a system and a method for ultrasensitive detection of microRNAs related to acute myocardial infarction. According to the method, the trans-cleavage activity of a designed circular RNA activator (CA-RNA) and Cas13a protein is utilized, Cas13a is activated through a target microRNA to cut a continuous uracil (U) structure in the CA-RNA, the circular conformation of the Cas13a is destroyed, a linear activator is released, and then multi-round cascade signal amplification is triggered. A centrifugal digital micro-fluidic chip is combined, a reaction system is divided into a large number of independent micro-chambers, positive micro-chambers are counted according to Poisson distribution, and accurate quantification of target microRNA is achieved. The system does not need reverse transcription and complex instruments, can complete detection within 15 minutes at 37 DEG C, has the detection limit reaching the almole level, has the advantages of simplicity and convenience in operation, high sensitivity, strong specificity, good universality and the like, and is suitable for early clinical diagnosis of acute myocardial infarction.
Nº publicación: CN121975928A 05/05/2026
Solicitante:
HANGZHOU FIRST PEOPLES HOSPITAL
\u676D\u5DDE\u5E02\u7B2C\u4E00\u4EBA\u6C11\u533B\u9662
Resumen de: CN121975928A
The invention relates to a kit for screening dilated cardiomyopathy. The kit comprises a reagent for detecting one or more of genes of TP53, TNF, IL1beta, JUN, CD8A, TLR4, UBB, CTLA4, CXCL8 and NFKBIA. The kit provided by the invention is high in detection efficiency and low in detection cost, provides important reference basis for diagnosis and prognosis judgment of patients with dilated cardiomyopathy, and can remarkably improve the survival rate of the patients.
BOPI
Sede Electrónica
